|A CT scan of the equine distal limb reveals the bony architecture. Image courtesy of Alex zur Linden, DVM, DACVR, Assistant Professor of Radiology at Ontario Veterinary College.|
By now, most Hoof Blog readers know the mechanism behind degenerative bone loss that is so clearly illustrated by foot conditions like pedal osteitis and navicular degeneration. Tildren is the current great hope for treatment of those conditions, although only now it has only been studied in navicular disease and bone spavin. Still, there's hope!
Enter a new hope this week, thanks to a study from the University of Pennsylvania, as mentioned in the journal Nature Medicine. Senior author Yongwon Choi, PhD, professor of Pathology and Laboratory Medicine at the University of Pennsylvania and colleagues report their findings.
To quote from their press release:
"The basic principles behind bone metabolism are largely understood, hence a handful of drugs treating osteoporosis are available. Most drugs inhibit osteoclasts, which cause bone decay. But there is also at least one that stimulates osteoblasts, enhancing bone formation. A combined treatment will not only prevent the occurrence of osteoporosis, but also make the quality of bone even better.
"Our discovery proves that inhibiting osteoclasts while simultaneously stimulating new bone formation can be done.
"Bone health is maintained by the balanced activities of osteoblasts and osteoclasts. The study shows that the inactivation of gene Atp6v0d2 in mice results in dramatically increased bone mass due to defective osteoclasts as well as enhanced bone formation.
"These findings may provide some clarity into the regulation of bone metabolism and show that targeting the function of a single gene could possibly inhibit bone decay while stimulating bone formation."
Before you start lining up all those lame horses, please realize that it may be a while before this gene therapy becomes a reality and trickles down to equine medicine. Then again, the equine model may be a good one for experimentation. Let's hope!